Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial
Open Access
- 2 June 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 29 (15), 1827-1833
- https://doi.org/10.1093/eurheartj/ehn236
Abstract
Elderly patients are at high risk from non-ST-segment elevation acute coronary syndromes (NSTE ACS) as well as from treatment-related complications. Age-associated changes in physiology may alter the risk and benefit expected from therapy. The SYNERGY database was used to study the influence of age on treatment outcomes with enoxaparin vs. unfractionated heparin (UFH) in patients with high-risk NSTE ACS. Age was analysed as a continuous and categorical variable (P = 0.002], 30-day death (ROR: 1.54, P < 0.0001), and 1-year death (ROR: 1.47, P < 0.0001), as well with TIMI major bleeding (ROR: 1.21, P = 0.001), GUSTO severe bleeding (ROR: 1.20, P = 0.047), and transfusion (ROR: 1.04, P = 0.324). Although there was a higher rate of GUSTO severe bleeding noted with enoxaparin in elderly patients, the overall relationships between treatment (UFH or enoxaparin) and outcomes did not vary significantly as a function of the patient's age. Although higher rates of adverse events are seen in the oldest subgroup (age ≥75 years) treated with enoxaparin, statistical comparisons confirm similar efficacy and safety of enoxaparin and UFH across age subgroups as was demonstrated overall in SYNERGY.Keywords
This publication has 27 references indexed in Scilit:
- Acute Coronary Care in the Elderly, Part ICirculation, 2007
- Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of CardiologyEuropean Heart Journal, 2007
- Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25European Heart Journal, 2007
- Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trialAmerican Heart Journal, 2006
- Clinical Benefit of Enoxaparin in Patients With High-Risk Acute Coronary Syndromes Without ST Elevations in Clinical PracticeThe American Journal of Cardiology, 2006
- Evolution in Cardiovascular Care for Elderly Patients With Non–ST-Segment Elevation Acute Coronary SyndromesJournal of the American College of Cardiology, 2005
- Impact of age on management and outcome of acute coronary syndrome: Observations from the global registry of acute coronary events (GRACE)American Heart Journal, 2005
- Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trialPublished by Oxford University Press (OUP) ,2004
- Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysisThe Lancet, 2000
- Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome)Published by Oxford University Press (OUP) ,1999